Live
- Gentle in manner, resolute in convictions: Sonia Gandhi pens emotional note for Dr. Manmohan Singh
- 2024: A landmark year for India's defence achievements and breakthroughs
- 2025 Horoscopes: Insights and Guidance by Pt. Umesh Chandra Pant
- Osamu Suzuki was a legendary figure in global auto industry: PM Modi
- “AMOEBA”: Celebrating the Journey of Telugu Entrepreneur Sri Motaparti Siva Rama Vara Prasad
- Sachin Khedekar recites a poem from director Feroz Abbas Khan’s powerful new play, ‘Hind 1957’
- NABL-QCI appoints Dr. Sandip Shah as chairperson
- Centre transfers Rs 2.23 lakh crore for 1,206 schemes under Direct Benefit Transfer
- BGT 2024-25: Watching Konstas bat reminds me of Symonds, says Hayden
- 75 iconic lighthouses in India saw more than 10 lakh visitors till September
Zydus gets USFDA nod for generic anti-pregnancy medication
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
The company has received final approval from the US Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg per day), the drug firm said in a statement.
Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy.
The transdermal patch will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, Zydus Lifesciences said.
As per IQVIA MAT data, Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg) had annual sales of USD 330 million in the US market. Shares of the company settled 0.93 per cent up at Rs 645.65 apiece on the BSE.
